Global MPN Scientific Foundation is proud to announce the creation of its Medical Advisory Board, a group of internationally recognized physicians and researchers who will provide scientific and clinical guidance to support the Foundation’s mission in myeloproliferative neoplasms (MPN).The Medical Advisory Board brings together leading expertise in hematology, oncology, clinical research, patient education and MPN care. Its role will be to help strengthen Global MPN’s educational initiatives, su

Peter Löffelhardt speaks with Prof. Florian Heidel about the advances presented at EHA 2026, the future of combination therapies and the POIESIS clinical trial for people living with myelofibrosis.

On Friday, April 24th, 2026, there’s a new webinar focused on Essential Thrombocythemia (ET) and the future of treatment options.This session will be led by Prof. Lucia Masarova, MD, Assistant Professor in the Department of Leukemia, Division of Cancer Medicine at MD Anderson Cancer Center (USA), and moderated by Peter Löffelhardt, Founder & CEO of GMPNSF.ET is often perceived as a less severe MPN, which can sometimes be seen to have fewer research opportunities and less visibility. However, ong

The recent webinar held in recognition of Chinese Platelets Day (March 20th, 2026) marked a great success and highlighted the importance of international collaboration in the MPN community.Organized by MPN China with the participation of the Global MPN Scientific Foundation, this event brought together patients, advocates, and experts from different countries to share knowledge and perspectives on the role of platelets in myeloproliferative neoplasms (MPNs).Content guide • A meaningful internati

We are very pleased to share an important milestone for the MPN community!The Global MPN Scientific Foundation is now an official member of Cancer Patients Europe (CPE), a leading European network that brings together patient organizations to strengthen the voice of people living with cancer across Europe.Source: https://cancerpatientseurope.org/about-us/ This step represents an important opportunity to ensure that myeloproliferative neoplasms (MPNs) are better represented at a European level, h